Headquarters: Copenhagen, Denmark
CEO: Dr. Bo Rode Hansen
SEK as of July 1, 2023
|Company||Market Cap (USD)|
|Novo Nordisk||$329.83 B|
|Vertex Pharmaceuticals Incorporated||$88.79 B|
|CSL Limited||$85.00 B|
|Marinomed Biotech AG||$84.73 B|
|Regeneron Pharmaceuticals, Inc.||$78.88 B|
Scandion Oncology A/S, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. Its products under development include SCO-101, which is in Phase II clinical trial for use in the treatment of breast and colorectal cancers; and SCO-201, a late pre-clinical stage product for use in the treatment of solid tumors. Scandion Oncology A/S has a collaboration agreement with Alligator Bioscience AB to explore combination therapies for chemotherapy and immunooncology. The company was founded in 2017 and is based in Copenhagen, Denmark.
Unlock the Power of Financial AI:
Try Disfold AI Free for 7 Days!